What Patients With Cancer Need to Know About Leg Swelling and Clot Risk

Cancer and venous thromboembolism have a complex and clinically important relationship that every patient with a cancer diagnosis — and their family members and caregivers — should understand. Cancer is among the strongest acquired risk factors for deep vein thrombosis and pulmonary embolism, and venous thromboembolism is one of the leading causes of death in cancer patients after the cancer itself. Recognizing the elevated risk, understanding the mechanisms behind it, and knowing when to seek urgent evaluation of leg symptoms are critical aspects of safe cancer management.
The mechanisms by which cancer promotes venous thrombosis are multiple and synergistic. Tumor cells produce a range of procoagulant factors — including tissue factor, cancer procoagulant, and inflammatory cytokines — that activate the coagulation cascade and create a chronically hypercoagulable state in the blood of cancer patients. This biochemical prothrombotic tendency is amplified by the physical effects of tumor masses compressing adjacent veins and by the reduced mobility common in patients experiencing cancer-related fatigue and debility.
Cancer treatments add further thrombotic risk. Certain chemotherapy agents — particularly platins, antiangiogenic agents, and thalidomide-based regimens — are independently associated with significantly elevated DVT risk. Central venous catheters, widely used for chemotherapy administration, create a foreign body within the venous system that can trigger catheter-related thrombosis. Surgical treatment of cancer, combined with the procoagulant state of the malignancy itself, creates a particularly high-risk perioperative period for venous thrombosis.
The consequences of DVT and pulmonary embolism in cancer patients are more severe than in the general population. Cancer patients tolerate pulmonary embolism less well, have higher rates of recurrent thrombosis during anticoagulation, and face more complex anticoagulation management given the interactions between their cancer treatments, their bleeding risk from thrombocytopenia and mucositis, and the standard anticoagulant medications. Low molecular weight heparin and, more recently, direct oral anticoagulants have been studied specifically in cancer-associated thrombosis and have established management roles.
Cancer patients experiencing leg swelling should report this symptom to their oncology team without delay, explicitly rather than waiting for a scheduled appointment if the swelling is new, sudden, or unilateral. The high baseline DVT risk in cancer patients means that the threshold for DVT investigation should be lower than in the general population, and prompt diagnosis and treatment can prevent the potentially fatal complication of pulmonary embolism. Many cancer treatment centers have developed specific protocols for the rapid evaluation and management of venous thromboembolism in their patients, reflecting the critical importance of this complication in the cancer care setting.